BioCentury
ARTICLE | Company News

Sanofi expands multitargeting toolbox with Biomunex deal

January 17, 2019 6:57 PM UTC

Sanofi (Euronext:SAN; NASDAQ:SNY) has expanded its toolbox for developing multispecific modalities through a licensing deal with Biomunex Pharmaceuticals (Paris, France).

The deal gives Sanofi access to Biomunex's Plug-and-Play BiXAb platform, which generates bi-specific and multispecific antibody therapies from any pair of monospecific mAbs. The platform can generate antibodies to treat cancer and immune-mediated inflammatory or infectious diseases...